Milsom Ian, Axelsen Susanne, Kulseng-Hansen Sigurd, Mattiasson Anders, Nilsson Carl Gustaf, Wickstrøm Jannie
Department of Obstetrics & Gynecology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
Acta Obstet Gynecol Scand. 2009;88(6):693-9. doi: 10.1080/00016340902849738.
The purpose of the present analysis was to analyze and compare the cost-effectiveness of solifenacin flexible dosing (5-10 mg) with tolterodine 4 mg sustained release (SR) or placebo (assumed to be comparable to no treatment) for patients with overactive bladder (OAB) symptoms.
A decision-analytic model was constructed.
Costs and effects were evaluated for the three treatment options in a one-year timeframe. Costs included were treatment costs, cost of pad use, and patients productivity loss based on data from the Nordic countries.
Results from two randomized controlled trials were used as input data in the cost-effectiveness analysis.
Quality adjusted life years and incremental cost-effectiveness ratio.
Solifenacin flexible dosing was more effective with respect to reducing OAB symptoms compared to both placebo and tolterodine 4 mg. Treatment with both solifenacin and tolterodine was more costly compared to placebo, but treatment with solifenacin was a less costly alternative compared to tolterodine 4 mg SR. Sensitivity analyses revealed that the conclusions were robust.
Solifenacin flexible dosing was a cost-effective treatment alternative compared to tolterodine 4 mg SR.
本分析旨在分析和比较索利那新灵活剂量（5 - 10毫克）与托特罗定4毫克缓释制剂（SR）或安慰剂（假定与未治疗相当）治疗膀胱过度活动症（OAB）症状患者的成本效益。
构建了一个决策分析模型。
在一年时间范围内评估三种治疗方案的成本和效果。纳入的成本包括治疗成本、护垫使用成本以及基于北欧国家数据的患者生产力损失。
两项随机对照试验的结果用作成本效益分析的输入数据。
质量调整生命年和增量成本效益比。
与安慰剂和托特罗定4毫克相比，索利那新灵活剂量在减轻OAB症状方面更有效。与安慰剂相比，索利那新和托特罗定治疗成本更高，但与托特罗定4毫克SR相比，索利那新治疗成本更低。敏感性分析表明结论可靠。
与托特罗定4毫克SR相比，索利那新灵活剂量是一种具有成本效益的治疗选择。
